Condition: Angelman Syndrome · Sponsor: Ionis Pharmaceuticals, Inc.
The purpose of this study is to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.
This description comes directly from the study's public registry record.
Ionis Pharmaceuticals, Inc. · (844) 285-7172 · IonisION582-CS2@clinicaltrialmedia.com
Always discuss trial participation with your own doctor first.
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Rady Children's Hospital | San Diego, California, United States | Recruiting |
| Colorado Children's Hospital Research Institute | Aurora, Colorado, United States | Recruiting |
| Children's National Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Nicklaus Children's Hospital | Miami, Florida, United States | Recruiting |
| Children's Healthcare of Atlanta | Atlanta, Georgia, United States | Recruiting |
| Rush University Medical Center | Chicago, Illinois, United States | Recruiting |
| Boston Children's Hospital | Boston, Massachusetts, United States | Recruiting |
| Children's Mercy | Kansas City, Missouri, United States | Recruiting |
| Ichan School of Medicine at Mount Sinai | New York, New York, United States | Recruiting |
| Columbia University Irving Medical Center | New York, New York, United States | Recruiting |
| University of North Carolina at Chapel Hill School of Medicine | Carrboro, North Carolina, United States | Recruiting |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06914609